Taiwan Bio Therapeutics (ROCO:6892) Ending Cash Position: NT$529.6 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
29 GF Score
Price NT$26.20
GF Value NT$14.64
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics Ending Cash Position?

Taiwan Bio Therapeutics ROCO:6892 -2.78% 29 Ending Cash Position is NT$529.6 Mil as of Jun. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 29/100 and a GF Value™ of NT$14.64 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Taiwan Bio Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2025 was NT$529.6 Mil.

Taiwan Bio Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 (NT$677.7 Mil) to Mar. 2025 (NT$588.4 Mil) and declined from Mar. 2025 (NT$588.4 Mil) to Jun. 2025 (NT$529.6 Mil).

Taiwan Bio Therapeutics's annual Ending Cash Position increased from Dec. 2023 (NT$248.1 Mil) to Dec. 2024 (NT$677.7 Mil) but then declined from Dec. 2024 (NT$677.7 Mil) to Dec. 2025 (NT$290.4 Mil).

Taiwan Bio Therapeutics Ending Cash Position Related Terms

Taiwan Bio Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics Ending Cash Position Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 59.70 245.89 248.14 677.69 290.40

Taiwan Bio Therapeutics Quarterly Data
Mar24 Sep24 Dec24 Mar25 Jun25
Ending Cash Position 558.07 350.76 677.69 588.41 529.60
ROCO:6892
29GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Bio Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Taiwan Bio Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=677.694+-387.299
=290.4

Taiwan Bio Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=588.407+-58.804
=529.6

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$529.6 Mil mean?
Taiwan Bio Therapeutics (ROCO:6892) has a Ending Cash Position of NT$529.6 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Taiwan Bio Therapeutics and its competitors.
Is Taiwan Bio Therapeutics' Ending Cash Position too high?
Taiwan Bio Therapeutics' current Ending Cash Position is NT$529.6 Mil. Overall, Taiwan Bio Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' Ending Cash Position compare to VRTX and REGN?
Taiwan Bio Therapeutics' Ending Cash Position of NT$529.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current Ending Cash Position is NT$529.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.64, compared to a current price of NT$26.20 — trading 79% above its estimated fair value. The current Ending Cash Position is NT$529.6 Mil. Taiwan Bio Therapeutics' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current Ending Cash Position is NT$529.6 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$26.20 is trading 79% above its estimated GF Value™ of NT$14.64. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • Ending Cash Position: NT$529.6 Mil
  • GF Value™: NT$14.64 vs. price of NT$26.20 (79% above fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
29GF Score

Get the complete analysis for ROCO:6892

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.20
Price
NT$14.64
GF Value